AcquisitionsAug 6, 2026, 07:02 AM
Harrow to Acquire TYRVAYA® Nasal Spray for Up to $100M
AI Summary
Harrow, Inc. announced a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. for an upfront cash payment of $30 million and up to $70 million in contingent milestone payments, totaling up to $100 million. This acquisition significantly expands Harrow's dry eye portfolio, complementing its VEVYE franchise by offering a differentiated treatment option. The company expects to fund the upfront payment with cash on hand, with the transaction anticipated to close in the second half of 2026.
Key Highlights
- Harrow to acquire TYRVAYA® (varenicline solution) nasal spray from Viatris Inc.
- Upfront cash payment of $30 million at closing.
- Contingent milestone payments up to $70 million, tied to net sales.
- Total potential consideration for the acquisition is up to $100 million.
- Acquisition expected to close in the second half of 2026.
- TYRVAYA is approved in the U.S., China, and Taiwan.
- Harrow expects to fund the upfront payment using cash on hand.
- Acquisition expands Harrow's dry eye portfolio, complementing VEVYE franchise.
Price Impact
More from HROW